Morgan Stanley’s TFF Pharmaceuticals, Inc. Common Stock TFFP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-32
| Closed | -$64 | – | 8170 |
|
|
2024
Q3 | $64 | Hold |
32
| – | – | ﹤0.01% | 7512 |
|
|
2024
Q2 | $53 | Hold |
32
| – | – | ﹤0.01% | 7478 |
|
|
2024
Q1 | $193 | Sell |
32
-32
| -50% | -$209 | ﹤0.01% | 7314 |
|
|
2023
Q4 | $450 | Sell |
64
-9
| -12% | -$70 | ﹤0.01% | 7291 |
|
|
2023
Q3 | $636 | Hold |
73
| – | – | ﹤0.01% | 7284 |
|
|
2023
Q2 | $854 | Sell |
73
-8
| -10% | -$115 | ﹤0.01% | 7321 |
|
|
2023
Q1 | $1.38K | Sell |
81
-241
| -75% | -$5.22K | ﹤0.01% | 7299 |
|
|
2022
Q4 | $8.46K | Buy |
322
+241
| +298% | +$11.4K | ﹤0.01% | 6992 |
|
|
2022
Q3 | $8K | Sell |
81
-198
| -71% | -$26.8K | ﹤0.01% | 7160 |
|
|
2022
Q2 | $39K | Buy |
279
+110
| +65% | +$15.3K | ﹤0.01% | 6717 |
|
|
2022
Q1 | $26K | Sell |
169
-18
| -10% | -$2.91K | ﹤0.01% | 7028 |
|
|
2021
Q4 | $43K | Sell |
187
-55
| -23% | -$10.6K | ﹤0.01% | 6887 |
|
|
2021
Q3 | $47K | Sell |
242
-926
| -79% | -$197K | ﹤0.01% | 6754 |
|
|
2021
Q2 | $281K | Buy |
1,168
+480
| +70% | +$132K | ﹤0.01% | 5846 |
|
|
2021
Q1 | $233K | Buy |
688
+658
| +2,193% | +$268K | ﹤0.01% | 5574 |
|
|
2020
Q4 | $11K | Buy |
30
+6
| +25% | +$2.31K | ﹤0.01% | 6613 |
|
|
2020
Q3 | $11K | Buy |
+24
| New | +$6.77K | ﹤0.01% | 6257 |
|
|
2020
Q1 | – | Sell |
-82
| Closed | -$11K | – | 6745 |
|
|
2019
Q4 | $11K | Buy |
+82
| New | +$10.5K | ﹤0.01% | 6247 |
|
Other funds holding TFFP
Morgan Stanley's TFFP Position: Q4 2024 in Review
Morgan Stanley sold out of TFF Pharmaceuticals, Inc. Common Stock (TFFP) in Q4 2024, closing a stake of 32 shares — an estimated $64 sold.
Morgan Stanley first reported a position in TFFP in Q4 2019 and held it in 18 quarters. The position peaked at $281K in Q2 2021. 4 funds tracked by Wall St. Rank hold TFFP as of Q4 2024.
- Morgan Stanley reported no remaining TFF Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Morgan Stanley sold 32 TFF Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $64.
- Morgan Stanley first reported a position in TFF Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 18 quarters.
- Morgan Stanley's TFF Pharmaceuticals, Inc. Common Stock position peaked at $281K in Q2 2021.
- 4 funds tracked by Wall St. Rank held TFF Pharmaceuticals, Inc. Common Stock as of Q4 2024.
Based on Morgan Stanley's 13F filing for Q4 2024, filed 14 Feb 2025.